Pinealon (10mg)

Pinealon's name points to the pineal gland. The peptide itself was pulled out of Cortexin, a neuroprotective polypeptide mixture made from bovine and porcine cerebral cortex.^[2] Glu-Asp-Arg was the most common three-amino-acid sequence in that extract, so Khavinson's group isolated it and synthesized a standalone version to see if the short fragment did anything on its own.

The pineal branding comes from a separate, overlapping thread. The same EDR sequence has also turned up in pineal-derived preparations, which is why older research summaries and marketing copy file Pinealon under "pineal bioregulators" next to Epitalon. Cortical origin and pineal association are two different claims. They get blurred often enough that it's worth keeping them apart when you're reading an older paper or a vendor page.

Searches for "Pinealon (bioregulator)" usually mean the term literally, so it's worth defining once. In the Khavinson framework, a bioregulator is a short peptide, most under eight amino acids, proposed to act on gene expression inside a specific tissue type rather than through a cell-surface receptor. Pinealon, Epitalon, and roughly a dozen related compounds fall under that label. It's a research classification, not a regulatory one. No health authority defines or approves a product category called "bioregulator."

The paper researchers cite most often is a 2011 Rejuvenation Research study using rat cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells.^[2] The design: expose the cells to a known oxidative trigger, ouabain at 100 nM or homocysteine at 500 micromolar, then add Pinealon and measure free-radical accumulation by flow cytometry.

A 100 nM dose of Pinealon fully blocked the ouabain-induced rise in reactive oxygen species. Against homocysteine, 500 nM did the same. Downstream, Pinealon delayed ERK 1/2 activation from 2.5 minutes to about 20 minutes in the homocysteine condition, and in PC12 cells, concentrations between 50 and 500 nM shifted the cell-cycle distribution away from the G1 phase.^[2] The antioxidant effect and the drop in necrotic cell death both leveled off around 100 to 500 nM, while the cell-cycle shift kept scaling past that point, a split the authors used to argue Pinealon does more than absorb free radicals.

All of that is one paper, in three cell lines, none of them human tissue and none of them a live animal. Useful for designing a comparator arm. Not evidence of anything happening in a body.

A 2012 study from the same research network tested Pinealon in pregnant rats with induced hyperhomocysteinemia, a metabolic stressor tied to fetal neurodevelopmental disruption, and reported that the peptide protected offspring against some of the resulting damage.^[3] A 2014 paper from a different institutional group ran a separate comparison: Pinealon against Cortexin in old rats under acute hypoxic stress, reading out serum cytokines and caspase-3 activity in brain tissue. The two peptides split the results, each doing more on some endpoints than the other.^[4]

Both are small, non-blinded rodent studies published in Russian-language or Russian-affiliated journals. Neither has an independent replication outside that network. That's a real gap, worth naming in any protocol that leans on these papers. It's a reason for caution, not a reason to throw the data out.

Khavinson's framework holds that Pinealon and related short peptides bind gene-promoter DNA directly and adjust transcription from inside the nucleus, instead of signaling through a cell-surface receptor. A 2019 physical-chemistry paper modeled how monovalent and divalent ions affect the EDR peptide's interaction with DNA, adding an outside lab's angle to the mechanism.^[5]

What's still missing, more than fifteen years after the idea was proposed, is a structural study, X-ray or cryo-EM, showing a three-residue peptide bound sequence-specifically to a DNA promoter. A folded DNA-binding domain usually needs more scaffolding than three amino acids can provide. Read the genomic-interaction model as a proposed mechanism backed by fluorescence and computational data. It isn't a settled fact.

Pinealon (Glu-Asp-Arg, three residues) and Epitalon (Ala-Glu-Asp-Gly, four residues) both came out of Khavinson's bioregulator program and both get filed under pineal research, but they aren't interchangeable. Epitalon's literature is about telomerase activity and rodent lifespan studies. Pinealon's is about oxidative stress, neuronal viability, and cortical gene expression, plus a separate paper reporting that short peptides including EDR stimulate serotonin-related gene expression in cultured brain-cortex cells.^[1]

Their regulatory footprint at home differs too. Several related Khavinson bioregulators hold Russian Federation drug registration. Pinealon and Epitalon don't; they're sold there as supplement-tier products. Neither is an FDA-approved drug in the United States. Tetrava Labs sells both strictly as Research Use Only laboratory reagents, and nothing in this section should be read as a recommendation to swap one for the other in a study design.

"Pinealon peptide protocol" searches usually want a human schedule. This page doesn't have one, and Tetrava Labs won't publish one, because Pinealon is a laboratory reagent, not an approved product with a dosing label.

What the published protocols do specify is concentration and timing for a given assay: nanomolar-range doses for the cell-culture oxidative-stress work cited above, milligram-per-kilogram dosing scaled for rat body weight in the hyperhomocysteinemia and hypoxia studies, each with its own exposure window and readout. None of that scales to a human number through simple arithmetic, and this page won't do that conversion. If your protocol needs a concentration or exposure time, pull it from the primary paper for your specific model, not from a rearranged version of someone else's rat study.

Pinealon ships lyophilized. That's what keeps a tripeptide this small stable in transit. Store sealed vials at -20°C, skip repeated freeze-thaw cycles, and reconstitute under sterile technique with a protocol-appropriate diluent right before use.

Once reconstituted, hold the working solution per your lab's SOP and log the diluent lot, concentration, date, and operator in the ELN, so the prep stays traceable against the batch Certificate of Analysis. A "99% pure, lab-tested" claim only means something if you can match it to that specific lot's COA, not a generic PDF reused across batches. Tetrava Labs also lists Pinealon capsules for labs running an oral-route design instead of a reconstituted vial. None of this is dosing or administration guidance for a person or an animal. It's lab-prep documentation for whoever is running the assay.